In The News Posted September 30, 2021 Share Posted September 30, 2021 NEW HAVEN, Conn., Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions,...View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts